Darunavir absorption is reduced without food. When the drug is taken without a booster, it should be swallowed with a meal to ensure adequate plasma levels.
UK-manufactured darunavir tablets typically bear the imprint “DAR 800” or “DAR 600,” indicating the strength (800 mg or 600 mg) and the manufacturer’s identification code.
Standard workplace drug screens in the UK test for substances of abuse (e.g., cannabis, opioids) and do not include antiretroviral medications like darunavir.
Darunavir is listed on the NHS Drug Tariff and is reimbursed for qualifying patients. Its price is comparable to other boosted protease inhibitors, but exact costs depend on the prescribing centre and any available discounts.
Yes. Carry the medication in its original packaging with a copy of the prescription. For trips longer than a few weeks, obtain a letter from your clinician stating the medical necessity, which may be required by customs authorities.
St John’s wort is a strong CYP3A4 inducer and can markedly lower darunavir levels, potentially compromising viral suppression. Patients should disclose all herbal products to their clinician.
Both tablets contain darunavir; the dosage selected depends on the boosting agent and the patient’s resistance profile. The 800 mg tablet is standard when used with ritonavir, while the 600 mg tablet is often paired with cobicistat.
When boosted with ritonavir, darunavir typically reaches steady state after about 4-5 days of once-daily dosing.
Darunavir is excreted in breast milk in low amounts. The UK guidelines advise caution; the benefits of breastfeeding must be weighed against the potential risk of HIV transmission and drug exposure.
If the missed dose is less than 8 hours from the scheduled time, take it as soon as possible. If more than 8 hours have passed, skip the missed dose and resume the regular dosing schedule the following day. Do not double-dose.
Darunavir is a protease inhibitor used in the treatment of human immunodeficiency virus (HIV) infection. It is available in tablet form at strengths of 600 mg and 800 mg and is prescribed in the United Kingdom under the supervision of the Medicines and Healthcare products Regulatory Agency (MHRA). Darunavir is typically prescribed with a pharmacokinetic booster such as ritonavir or cobicistat to achieve sufficient blood levels.
Darunavir blocks the HIV-1 protease enzyme, an essential protein that the virus needs to cleave newly synthesized viral polyproteins into functional components. By inhibiting this enzyme, darunavir prevents the maturation of infectious viral particles, reducing the amount of circulating virus. The drug is taken orally, absorbed from the gastrointestinal tract, and extensively metabolised by the liver enzyme CYP3A4. Because darunavir is a substrate of CYP3A4, co-administration with a booster that inhibits this enzyme (e.g., ritonavir 100 mg twice daily) markedly increases its plasma concentration, allowing once-daily dosing in most regimens.
In the UK, darunavir is approved for use in adults and adolescents (≥12 years) with HIV-1 infection who have treatment-experienced disease or harbour virus resistant to other protease inhibitors. It is part of combination antiretroviral therapy (cART) and is prescribed together with other agents such as nucleos(t)ide reverse transcriptase inhibitors (NRTIs). The medication helps achieve and maintain viral suppression (HIV-RNA < 50 copies/mL) and supports immune recovery as measured by rising CD4 + cell counts.
Dosing must be individualized by a healthcare provider based on viral resistance profile, liver function, and concomitant medications.
Patients should contact their clinician promptly if they develop severe rash, jaundice, persistent diarrhoea, or any symptoms suggestive of an allergic reaction.
This article provides educational information about darunavir and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
